Literature DB >> 15180667

Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model.

Scott M Berry1, Donald A Berry.   

Abstract

Multiple comparisons and other multiplicities are among the most difficult of problems that face statisticians, frequentists, and Bayesians alike. An example is the analysis of the many types of adverse events (AEs) that are recorded in drug clinical trials. We propose a three-level hierarchical mixed model. The most basic level is type of AE. The second level is body system, each of which contains a number of types of possibly related AEs. The highest level is the collection of all body systems. Our analysis allows for borrowing across body systems, but there is greater potential-depending on the actual data-for borrowing within each body system. The probability that a drug has caused a type of AE is greater if its rate is elevated for several types of AEs within the same body system than if the AEs with elevated rates were in different body systems. We give examples to illustrate our method and we describe its application to other types of problems.

Mesh:

Substances:

Year:  2004        PMID: 15180667     DOI: 10.1111/j.0006-341X.2004.00186.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  21 in total

1.  Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing.

Authors:  Colin John Crooks; David Prieto-Merino; Stephen J W Evans
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Terminological challenges in safety surveillance.

Authors:  Andrew Bate; Elliot G Brown; Stephen A Goldman; Manfred Hauben
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

3.  Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study.

Authors:  Xiaoyan Wang; George Hripcsak; Marianthi Markatou; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2009-03-04       Impact factor: 4.497

4.  Efficient methods for signal detection from correlated adverse events in clinical trials.

Authors:  Guoqing Diao; Guanghan F Liu; Donglin Zeng; William Wang; Xianming Tan; Joseph F Heyse; Joseph G Ibrahim
Journal:  Biometrics       Date:  2019-03-29       Impact factor: 2.571

5.  Sequential Tests of Multiple Hypotheses Controlling False Discovery and Nondiscovery Rates.

Authors:  Jay Bartroff; Jinlin Song
Journal:  Seq Anal       Date:  2020-05-13       Impact factor: 0.927

Review 6.  Novel data-mining methodologies for adverse drug event discovery and analysis.

Authors:  R Harpaz; W DuMouchel; N H Shah; D Madigan; P Ryan; C Friedman
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

7.  Bayesian decision theoretic multiple comparison procedures: an application to phage display data.

Authors:  Luis G León-Novelo; Peter Müller; Wahid Arap; Jessica Sun; Renata Pasqualini; Kim-Anh Do
Journal:  Biom J       Date:  2012-12-20       Impact factor: 2.207

8.  Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.

Authors:  Scott M Berry; Kristine R Broglio; Susan Groshen; Donald A Berry
Journal:  Clin Trials       Date:  2013-08-27       Impact factor: 2.486

9.  A hierarchical testing approach for detecting safety signals in clinical trials.

Authors:  Xianming Tan; Bingshu E Chen; Jianping Sun; Tejendra Patel; Joseph G Ibrahim
Journal:  Stat Med       Date:  2020-02-12       Impact factor: 2.373

10.  Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation.

Authors:  Evan Mayo-Wilson; Xiwei Chen; Riaz Qureshi; Stephanie Dickinson; Lilian Golzarri-Arroyo; Hwanhee Hong; Carsten Görg; Tianjing Li
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.